The U.S. Food and Drug Administration (FDA) has granted fast track designation to Alessa Therapeutics for its lead product ...

Enolen is currently being studied in a Phase 1 trial evaluating its safety, tolerability and preliminary efficacy for localized sustained delivery of enzalutamide into the prostate. Alessa expects to ...

An analysis of data on 945 patients with prostate cancer that is managed with active surveillance shows differences in outcomes depending on whether the patient was low or intermediate risk at ...

The rate of active surveillance as initial treatment increased from 2.0% in 2010 to 8.6% in 2020. The use of active surveillance in patients with intermediate-risk prostate cancer has increased in ...

Survival curves separated as early as 4 to 5 years after initiation of active surveillance or active treatment, investigators reported. Active surveillance (AS) should be cautiously offered to men ...

Stereotactic body radiation therapy (SBRT) is a safe and effective treatment for men with low- and intermediate-risk prostate cancer, according to a long-term, multi-institutional study. The study ...

A former prostate cancer patient who got the all-clear said taking part in a trial that cut his radiotherapy treatments ...

Please provide your email address to receive an email when new articles are posted on . Although active surveillance is acceptable for low-risk prostate cancers, the strategy may be risky for patients ...

SAN ANTONIO, October 22, 2018 -- Stereotactic body radiation therapy (SBRT) is a safe and effective treatment for men with low- and intermediate-risk prostate cancer, according to a long-term, ...

Utilization of active surveillance (AS) for prostate cancer is increasing. Optimal selection criteria for this approach are undefined and questions remain on how best to expand inclusion beyond ...